Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company Patrys (PAB) has been granted a U.S. patent for its deoxymab antibody platform
- The patent covers the use of two humanised antibodies in combination with radiosensitising agents that damage DNA and inhibit its repair
- Patrys’ deoxymabs can penetrate cancer cells and disrupt their DNA damage repair which help to treat various cancers
- The company believes that combining its deoxymabs with radiosensitising agents may provide a more “powerful” approach for treating cancer
- Excitingly, the new patent expands the company’s intellectual property portfolio which covers a range of different ways to use the novel deoxymabs for treating cancer
- Patrys’ shares are up 11.1 per cent and are trading at 3 cents
Patrys (PAB) has been granted a U.S. patent for its deoxymab antibody platform.
The patent covers the use of the PAT-DX1 and PAT DX3 humanised forms of the deoxymab antibody, in combination with radiosensitising agents (used for cancer treatment) that damage DNA or inhibit DNA from repairing.
Patrys’ deoxymabs can penetrate cancer cells and disrupt their DNA damage repair systems which have proven effective for treating certain cancers with PARP inhibiting drugs.
Most antibodies bind to cell surface markers. However, deoxymab penetrates into the cell nuclei which allows it to bind directly DNA where it can inhibit the DNA repair process.
Significantly, studies have shown that PAT-DX1 can cross the blood brain barrier, reduce tumour size and increase survival in multiple animal models of brain cancer and other cancers.
The company believes that combining its deoxymabs with radiosensitising agents may provide additional benefits and a more “powerful” approach for treating different cancers.
“The granting of this patent by the United States Patent and Trademark Office provides Patrys with additional intellectual property (IP) covering different ways that its deoxymab antibodies may be used for the treatment of patients with cancer,” CEO and Managing Director Dr James Campbell said.
“This protection provides Patrys with a range of options as it finalises its plans to commence the clinical development of its deoxymabs over the coming months,” he added.
Excitingly, the new patent expands Patrys’ IP portfolio by taking its number of granted patents for its deoxymabs to six across Europe, Japan, China and the U.S.
The patent is titled “Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair” and will expire in August 2033.
Patrys’ shares are up 11.1 per cent and are trading at 3 cents at 11:34 am AEDT.
